TITLE

Electrical Impact

PUB. DATE
October 2007
SOURCE
PN;Oct2007, Vol. 61 Issue 10, p40
SOURCE TYPE
Trade Publication
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the Andara Oscillating Field Stimulator (OFS) System from Cyberkinetics Inc.
ACCESSION #
26633735

 

Related Articles

  • Turning thought into action.  // R&D Magazine;Aug2006, Vol. 48 Issue 8, p31 

    The article reports on the development of the BrainGate Neural Interface System by researchers at Cyberkinetics Neurotechnology Systems Inc. The system is designed to restore functionality to a group of motor-impaired individuals. It is based on a platform technology to sense, transmit, analyze...

  • Brain waves. Hargreaves, Ben // Professional Engineering;3/7/2007, Vol. 20 Issue 5, p43 

    The article evaluates the Brain Gate brain-computer interface from Cyberkinetics Inc. INSET: NEW NERVES.

  • Cyberkinetics, NeuroMetrix in j-v; Ventana opens books.  // Medical Technology & Devices Week;11/19/2007, Vol. 5 Issue 46, p4 

    This article focuses on the joint venture formed between Cyberkinetics Neurotechnology Systems and NeuroMetrix to accelerate development of therapies for peripheral nerve damage based on Cyberkinetics' Andara oscillating field stimulator therapy platform. Cyberkinetics develops implantable...

  • PRODUCT BRIEFS.  // Medical Device Daily;12/13/2007, Vol. 11 Issue 226, p10 

    This section offers news briefs on the U.S. medical instruments industry. A letter was received by Cyberkinetics Neurotechnology Systems from the Food and Drug Administration (FDA) requesting additional analyses and data for its Humanitarian Device Exemption marketing application for the Andara...

  • Cyberkinetics, NeuroMetrix form j-v to develop new nerve injury device. Yoffee, Lynn // Medical Device Daily;2/20/2008, Vol. 12 Issue 34, p1 

    The article reports on the joint venture of Cyberkinetics Neurotechnology Systems with NeuroMetrix for the formation of the peripheral nerve injury repair (PNIR). They will develop and commercialize the Andard Oscillating Field Stimulator (OFS) for different peripheral nerve injury indications....

  • Cash-strapped Cyberkinetics may be pushed to bankruptcy. YOFFEE, LYNN // Medical Device Daily;11/12/2008, Vol. 12 Issue 221, p1 

    The article reports on the challenges facing Cyberkinetics Neurotechnology Systems, a start-up company that hopes to bring its acute spinal cord injury product Andara HDE to market. Based on a report it has filed with the U.S. Securities and Exchange Commission (SEC), the company admits that it...

  • New IP relates to Cyberkinetics' next-generation BrainGate device.  // Medical Device Daily;6/6/2007, Vol. 11 Issue 108, p4 

    The article reports the issuing of the U.S. patent called Microstructured Arrays for Cortex Interaction and Related Methods of Manufacture and Use, to Brown University and Massachusetts Institute of Technology. The patent is exclusively licensed to Cyberkinetics Neurotechnology Systems and is...

  • Cyberkinetics seeks HDE for nerve growth stimulator. Pedersen, Amanda // Biomedical Business & Technology;Mar2007, Vol. 30 Issue 3, p32 

    The article reports that Cyberkinetics Neurotechnology Systems is seeking from the U.S. Food and Drug Administration (FDA) a Humanitarian Device Exemption to obtain clearance for its Andara Oscillating Field Stimulator System, a nerve growth stimulator. According to Cyberkinetics, the nerve...

  • Neural Implant.  // Government Technology;Apr2004, Vol. 17 Issue 4, p12 

    Reports on the decision of Cyberkinetics to file an investigational device exemption with the U.S. Food and Drugs Administration to conduct a pilot clinical trial for the BrainGate neural implant in 2004 in the U.S. Number of quadriplegic patients who will receive the implant; Components of the...

  • Cyberkinetics Gives Update on BrainGate Clinical Trial.  // O&P Business News;5/15/2005, Vol. 14 Issue 10, p72 

    Reports on interim results of the pilot study of the BrainGateâ„¢ Neural Interface System from Cyberkinetics Neurotechnology Systems Inc. Primary goals of the pilot clinical study; Features of the BrainGate Neural Interface System brain-computer interface; Implications for the treatment of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics